Avrukibart vs risankizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

Avrukibart

Developed by Oruka Therapeutics

Phase 2 in Psoriasismonoclonal antibody
Partial signal

NCT07090330 · Phase 2 · active, not recruiting

This was a randomized, double-blind Phase 2 trial with 80 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: May 2030 · NCT07449702 (registry estimate)

Reported efficacy

Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). (met)

Result source: NCT07090330

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02684370 · Phase 3 · completed

This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.

Next expected readout: April 2028 · NCT04862286 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)

Result source: NCT02672852

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAvrukibartrisankizumab
PASI 75—Not reported85.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
PASI 90—Not reported75.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481
PASI 100—Not reported35.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
sPGA 0/1—Not reported87.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
DLQI, change—Not reported-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382

PASI 75

Avrukibart
—Not reported
risankizumab
85.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481

PASI 90

Avrukibart
—Not reported
risankizumab
75.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481

PASI 100

Avrukibart
—Not reported
risankizumab
35.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481

sPGA 0/1

Avrukibart
—Not reported
risankizumab
87.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481

DLQI, change

Avrukibart
—Not reported
risankizumab
-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Avrukibart
Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). NCT07090330 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Avrukibart: 0 of 4 rows · risankizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Dropout rate
1.6%Risankizumab (Part A)a
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
1%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0.7%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
2.3%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
0%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
26.2%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
3.4%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
16%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
11.1%
NCT03875508 · Phase 3 · registry result, not featured evidence
12.4%
NCT03875482 · Phase 3 · registry result, not featured evidence
7.9%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
70%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
70%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
4.8%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
4.9%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
9.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.3%Risankizumab (Part A)a
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
0.2%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
—Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
—Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
6.5%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
1.1%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
1.6%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0.9%
NCT03875508 · Phase 3 · registry result, not featured evidence
0%
NCT03875482 · Phase 3 · registry result, not featured evidence
0.6%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
—600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.4%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Serious AEs
2.3%Risankizumab (Part A)a
NCT02684370 · Phase 3
show 53 more results
5.4%Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
2%Risankizumab (Part A1)
NCT02672852 · Phase 3
11.7%Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
10%Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
0%Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
0%Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
0%Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
0%Part 3: Risankizumab
NCT04435600 · Phase 3
0%Part 4: Risankizumab
NCT04435600 · Phase 3
2%Risankizumab (Part A)
NCT02684357 · Phase 3
4.5%Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
5.7%Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
10.5%Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
3.3%Risankizumab (Part A)
NCT02694523 · Phase 3
4.1%Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
1.9%Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
5.9%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
5.9%Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
0.8%Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
0%Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
2.9%Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
6.9%Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
20%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
—Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
5.7%Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
6%Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
7%
NCT04102007 · Phase 3 · registry result, not featured evidence
25%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
50%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
20%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
1%
NCT03875482 · Phase 3 · registry result, not featured evidence
5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
1.7%
NCT03255382 · Phase 3 · registry result, not featured evidence
0%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
10%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
8.7%180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
13.8%90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.6%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.9%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
7.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.8%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
14.6%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
11.6%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
viral upper respiratory tract infection 6.6% (placebo 5.9%)
upper respiratory tract infection 5.6% (placebo 2%)
headache 3% (placebo 2%)
NCT02684370 · Phase 3
show 48 more results
viral upper respiratory tract infection 13.5% (placebo 5.9%)
upper respiratory tract infection 10.1% (placebo 2%)
headache 1.7% (placebo 2%)
NCT02684370 · Phase 3
nasopharyngitis 5.2% (placebo 6%)
headache 3.4% (placebo 0%)
arthralgia 1.7% (placebo 2%)
NCT02672852 · Phase 3
nasopharyngitis 20.7% (placebo 6%)
upper respiratory tract infection 14.4% (placebo 5%)
arthralgia 9% (placebo 2%)
NCT02672852 · Phase 3
headache 16.7% (placebo 4.8%)
pyrexia 16.7% (placebo 0%)
abdominal pain 8.3% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 40% (placebo 9.5%)
covid-19 20% (placebo 9.5%)
conjunctivitis 10% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 22.7% (placebo 9.5%)
headache 18.2% (placebo 4.8%)
skin papilloma 13.6% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 18.5% (placebo 9.5%)
covid-19 9.3% (placebo 9.5%)
headache 5.6% (placebo 4.8%)
NCT04435600 · Phase 3
pyrexia 25% (placebo 0%)
bacterial vaginosis 12.5% (placebo 0%)
chills 12.5% (placebo 0%)
NCT04435600 · Phase 3
cough 15.4% (placebo 4.8%)
upper respiratory tract infection 15.4% (placebo 4.8%)
blood potassium increased 7.7% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 31.3% (placebo 9.5%)
pyrexia 12.5% (placebo 0%)
cough 9.4% (placebo 4.8%)
NCT04435600 · Phase 3
upper respiratory tract infection 3.7% (placebo 2%)
viral upper respiratory tract infection 3.4% (placebo 2%)
influenza 2% (placebo 1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 11.7% (placebo 2%)
upper respiratory tract infection 8.2% (placebo 2%)
diarrhoea 2.1% (placebo 3.1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 26.4%
upper respiratory tract infection 7.5%
headache 5.7%
NCT02694523 · Phase 3
viral upper respiratory tract infection 23.7%
hypertension 7.9%
upper respiratory tract infection 7.9%
NCT02694523 · Phase 3
viral upper respiratory tract infection 8.6%
upper respiratory tract infection 7%
headache 4%
NCT02694523 · Phase 3
viral upper respiratory tract infection 13.3%
upper respiratory tract infection 11.6%
hypertension 3.1%
NCT02694523 · Phase 3
upper respiratory tract infection 7.3% (placebo 3.7%)
covid-19 3.6% (placebo 3.7%)
nasopharyngitis 3.6% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 7.4% (placebo 3.7%)
covid-19 3.7% (placebo 3.7%)
nasopharyngitis 3.7% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
covid-19 11%
nasopharyngitis 3.4%
headache 2.5%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 12.5%
nasopharyngitis 10.4%
hypertension 6.3%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 11.8%
nasopharyngitis 9.8%
upper respiratory tract infection 5.9%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 16.4%
nasopharyngitis 9.5%
hypertension 5.2%
NCT04908475 · Phase 4 · registry result, not featured evidence
150 mg
nasopharyngitis 22.1%
covid-19 16.6%
upper respiratory tract infection 14.4%
NCT03047395 · Phase 3 · registry result, not featured evidence
covid-19 2.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 14.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 8.6%
nasopharyngitis 5.7%
NCT04102007 · Phase 3 · registry result, not featured evidence
150 mg
viral upper respiratory tract infection 75%
otitis media 50%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
150 mg
dehydration 50%
abdominal pain upper 25%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
viral upper respiratory tract infection 60%
constipation 20%
diarrhoea 20%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
alanine aminotransferase increased 25%
aspartate aminotransferase increased 25%
erythema 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
upper respiratory tract infection 5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21.3%
upper respiratory tract infection 12.8%
arthralgia 5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
nasopharyngitis 58.3%
headache 8.3%
oropharyngeal pain 8.3%
NCT03255382 · Phase 3 · registry result, not featured evidence
600 mg
upper respiratory infection 50%
common cold 30%
covid-19 infection 30%
NCT05283135 · Phase 2 · registry result, not featured evidence
300 mg
upper respiratory infection 20%
bleeding internal hemorrhoids 10%
bursitis, left elbow 10%
NCT05283135 · Phase 2 · registry result, not featured evidence
180 mg
upper respiratory tract infection 17.4%
dermatitis contact 13%
nasopharyngitis 13%
NCT02203851 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 18.4%
upper respiratory tract infection 12.6%
arthralgia 10.3%
NCT02203851 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
oral herpes 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 18.2% (placebo 13.8%)
arthralgia 3.6% (placebo 1.7%)
back pain 1.8% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 20.4% (placebo 13.8%)
dental caries 7.4% (placebo 1.7%)
blood triglycerides increased 5.6% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
asteatosis 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
diabetes mellitus 5.2% (placebo 1.7%)
nasopharyngitis 5.2% (placebo 13.8%)
back pain 3.4% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 21.4% (placebo 13.8%)
hepatic function abnormal 5.4% (placebo 0%)
influenza 5.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
180 mg
nasopharyngitis 26.2%
arthralgia 7.1%
headache 7.1%
NCT02054481 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 34.1%
back pain 9.8%
gastroenteritis 9.8%
NCT02054481 · Phase 2 · registry result, not featured evidence
18 mg
nasopharyngitis 34.9%
headache 11.6%
folliculitis 7%
NCT02054481 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

PASI 90 74.5% (n=55) vs 1.7% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 34 more results
75.9% (n=58) vs 1.7% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
81% (n=42) vs 40% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
85.7% (n=42) vs 55% (n=40) Stelara @ 24wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
73.2% (n=41) vs 40% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
65.9% (n=41) vs 55% (n=40) Stelara @ 24wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
32.6% (n=43) vs 40% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
30.2% (n=43) vs 55% (n=40) Stelara @ 24wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
75.3% (n=304) vs 4.9% (n=102) placebo @ 16wk
NCT02684370 · Phase 3
75.3% (n=304) vs 42% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
81.9% (n=304) vs 44% (n=100) Ustekinumab @ 52wk
NCT02684370 · Phase 3
73.2% (n=407) vs 2% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
85.6% (n=111) vs 52.4% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
83.3% (n=12) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
64.8% (n=54) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
84.6% (n=13) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
76.7% (n=30) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
74.8% (n=294) vs 2% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
74.8% (n=294) vs 47.5% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
80.6% (n=294) vs 50.5% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
72.4% (n=301) vs 47.4% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
66% (n=53) vs 21.4% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
55.9% (n=118) vs 5.1% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
72.3% (n=83) vs 2.6% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
62.9% (n=105) vs 3.8% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
73.8% (n=164) vs 65.6% (n=163) Secukinumab @ 16wk
NCT03478787 · Phase 3 · registry result, not featured evidence
86.6% (n=164) vs 57.1% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
83.3% (n=60) vs 10% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
1.7% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
38.3% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
61.7% (n=60) vs 5% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
76.7% (n=60) vs 11.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
83.3% (n=60) vs 16.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
77.1% (n=83) vs 40% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
75.9% (n=83) vs 55% (n=40) Stelara @ 24wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
sPGA 0/1 92.7% (n=55) vs 10.3% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 36 more results
86.2% (n=58) vs 10.3% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
90.5% (n=42) vs 67.5% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
90.2% (n=41) vs 67.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
62.8% (n=43) vs 67.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
87.8% (n=304) vs 7.8% (n=102) placebo @ 16wk
NCT02684370 · Phase 3
87.8% (n=304) vs 63% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
82.2% (n=304) vs 65% (n=100) Ustekinumab @ 12wk
NCT02684370 · Phase 3
83.5% (n=407) vs 7% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
87.4% (n=111) vs 61.3% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
81.1% (n=111) vs 7.1% (n=225) placebo @ 104wk
NCT02672852 · Phase 3
83.3% (n=12) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
79.6% (n=54) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
84.6% (n=13) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
90% (n=30) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
83.3% (n=12) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
68.5% (n=54) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
84.6% (n=13) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
83.3% (n=30) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
83.7% (n=294) vs 5.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
83.7% (n=294) vs 61.6% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
82.3% (n=294) vs 64.6% (n=99) Ustekinumab @ 12wk
NCT02684357 · Phase 3
83.3% (n=294) vs 54.5% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
83.7% (n=301) vs 60.2% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
73.6% (n=53) vs 33.9% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
75.4% (n=118) vs 18.4% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
77.1% (n=83) vs 7.7% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
32.2% (n=87) vs 11.5% (n=87) placebo @ 16wk
NCT04713592 · Phase 3 · registry result, not featured evidence
78.1% (n=105) vs 9.6% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
87.8% (n=164) vs 58.3% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
33.3% (n=60) vs 3.3% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
81.7% (n=60) vs 15% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
90% (n=60) vs 33.3% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
91.7% (n=60) vs 31.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
93.3% (n=60) vs 48.3% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
93.3% (n=60) vs 38.3% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
90.4% (n=83) vs 67.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
sPGA (0 36.8% (n=304) vs 2% (n=102) placebo @ 16wk
responder rate · % of participants
NCT02684370 · Phase 3
show 15 more results
36.8% (n=304) vs 14% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
57.6% (n=304) vs 21% (n=100) Ustekinumab @ 52wk
NCT02684370 · Phase 3
46.4% (n=407) vs 1% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
51% (n=294) vs 3.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
51% (n=294) vs 25.3% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
59.5% (n=294) vs 30.3% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
39.6% (n=53) vs 7.1% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
50.9% (n=55) vs 5.6% (n=54) placebo @ 16wk
NCT05969223 · Phase 4
39% (n=105) vs 1.9% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
1.7% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
10% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
21.7% (n=60) vs 3.3% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
36.7% (n=60) vs 3.3% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
48.3% (n=60) vs 6.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
51.7% (n=60) vs 5% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI 100 32.7% (n=55) vs 0% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 27 more results
22.4% (n=58) vs 0% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
50% (n=42) vs 17.5% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
41.5% (n=41) vs 17.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
14% (n=43) vs 17.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
35.9% (n=304) vs 0% (n=102) placebo @ 16wk
NCT02684370 · Phase 3
35.9% (n=304) vs 12% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
56.3% (n=100) vs 21% (n=304) Ustekinumab @ 52wk
NCT02684370 · Phase 3
47.2% (n=407) vs 1% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
64% (n=111) vs 30.2% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
41.7% (n=12) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
40.7% (n=54) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
53.8% (n=13) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
43.3% (n=30) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
50.7% (n=294) vs 2% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
50.7% (n=294) vs 24.2% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
59.5% (n=294) vs 30.3% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
39.9% (n=301) vs 23% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
39.6% (n=53) vs 7.1% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
38.1% (n=105) vs 1.9% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
65.9% (n=164) vs 39.9% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
0% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
5% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
23.3% (n=60) vs 1.7% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
35% (n=60) vs 1.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
48.3% (n=60) vs 6.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
50% (n=60) vs 5% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
45.8% (n=83) vs 17.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
DLQI 0/1 65.8% (n=304) vs 7.8% (n=102) placebo @ 16wk
responder rate · % of participants
NCT02684370 · Phase 3
show 7 more results
65.8% (n=304) vs 43% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
65.4% (n=407) vs 3% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
66.7% (n=294) vs 4.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
66.7% (n=294) vs 46.5% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
60% (n=55) vs 3.7% (n=54) placebo @ 16wk
NCT05969223 · Phase 4
48.3% (n=60) vs 10% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
66.7% (n=60) vs 10% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI 75 94.5% (n=55) vs 8.6% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 29 more results
89.7% (n=58) vs 8.6% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
90.5% (n=42) vs 77.5% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.9% (n=42) vs 70% (n=40) Stelara @ 24wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
97.6% (n=41) vs 77.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.7% (n=41) vs 70% (n=40) Stelara @ 24wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
67.4% (n=43) vs 77.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
55.8% (n=43) vs 70% (n=40) Stelara @ 24wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
86.8% (n=304) vs 70% (n=100) Ustekinumab @ 12wk
NCT02684370 · Phase 3
88.7% (n=407) vs 8% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
92.8% (n=111) vs 71.6% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
83.3% (n=12) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
85.2% (n=54) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
92.3% (n=13) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
86.7% (n=30) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
88.8% (n=294) vs 69.7% (n=99) Ustekinumab @ 12wk
NCT02684357 · Phase 3
90.8% (n=294) vs 6.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
91.5% (n=294) vs 76.8% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
90.7% (n=301) vs 71.7% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
84.7% (n=118) vs 18.8% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
83.1% (n=83) vs 11.5% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
89.6% (n=164) vs 69.9% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
13.3% (n=60) vs 3.3% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
75% (n=60) vs 8.3% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
86.7% (n=60) vs 20% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
93.3% (n=60) vs 26.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
95% (n=60) vs 38.3% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
98.3% (n=60) vs 33.3% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
94% (n=83) vs 77.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.8% (n=83) vs 70% (n=40) Stelara @ 24wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
PSS Total -5.608 vs 0.157 placebo score @ 16wk
absolute change · score
NCT02684370 · Phase 3
show 3 more results
-6.013 vs -1.036 placebo score @ 16wk
NCT05969223 · Phase 4
-8.7 vs -5.5 Fumaderm score @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
-9.5 vs -5.6 Fumaderm score @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
sPGA 0/1 88.9% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 12 more results
94.5% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
96.3% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
84.5% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
68.8% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
70.4% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
63.6% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
57.4% (n=244) @ 16wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 140 Participants as posted
62.3% (n=244) @ 52wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 152 Participants as posted
81.5% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
66.7% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 50 95.2% (n=42) vs 87.5% (n=40) Stelara @ 12wk180 mg
responder rate · % of participants
NCT02054481 · Phase 2 · registry result, not featured evidence
show 13 more results
100% (n=41) vs 87.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
93% (n=43) vs 87.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
91.7% (n=12) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
90.7% (n=54) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
100% (n=13) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
96.7% (n=30) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
53.3% (n=60) vs 6.7% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
91.7% (n=60) vs 28.3% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 46.7% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 60% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 63.3% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 53.3% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
97.6% (n=83) vs 87.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
PASI 50 100% (n=32) @ 48wk180 mg
responder rate · % of participants
No placebo or comparator arm
NCT02203851 · Phase 2 · registry result, not featured evidence
show 4 more results
96.3% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
95.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
100% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 90 75% (n=4) @ 16wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03022045 · Phase 3 · registry result, not featured evidence
show 13 more results
100% (n=4) @ 16wk150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
85.2% (n=27) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
92.7% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
100% (n=4) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
60% (n=5) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
81.5% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
86.2% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
71.9% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
77.8% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
72.7% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
66.7% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
74.1% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 100 44.4% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 15 more results
41.8% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
40.7% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
43.1% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
77.8% (n=9) @ 28wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
66.7% (n=9) @ 40wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
44.4% (n=9) @ 52wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
88.9% (n=9) @ 28wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
66.7% (n=9) @ 40wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
44.4% (n=9) @ 52wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
50% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
55.6% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
54.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
25% (n=8) @ 16wk
NCT04435600 · Phase 3
46.3% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
55.6% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence

+ 47 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avrukibart's landscape · risankizumab's landscape